Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Belite Bio Inc
BLTE | US
161.26
USD-3.19
-1.94%
BLTE | US
Loading StockChartView...
About Belite Bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
161.26
Open
160.01
High
162.20
Low
157.77
Belite Bio Inc a clinical stage biopharmaceutical drug development company engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant) an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009 an anti-retinol binding protein 4 oral therapy targeting liver disease including non-alcoholic fatty liver disease nonalcoholic steatohepatitis type 2 diabetes and gout which is in the preclinical development phase. Belite Bio Inc was founded in 2016 and is based in San Diego California. Belite Bio Inc operates as a subsidiary of Lin Bioscience International Ltd.
View LessBLTE | US
Risk
52.3
Sharpe
3.25
Luna's Score
51/100
Recommendation
Hold
Luna says (BLTE | US)
What's Working
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
Midcap (2B - 10B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
46.3%1 month
52.3%3 months
49.0%6 months
58.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
15.21
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-35.61
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.54M
MarketCap
4.94B
MarketCap(USD)
4.94B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-41.44
Short ratio
8.66
Short perc.
2.16
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
23.43
Range1M
36.37
Range3M
53.39
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.60
Price X volume
14.49M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -35.61 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 15.21 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 48.97 | 72.80 | Lower Risk |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 4.94B | 3.66B | Market Leader |
